Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction

doi:10.1016/j.ahj.2008.06.002

American Heart Journal

Volume 156, Issue 2, Supplement, August 2008, Pages 1S-2S

https://doi.org/10.1016/j.ahj.2008.06.002 Get rights and content

Antiplatelet therapy plays a key role in preventing atherothrombotic complications in patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions. Despite such clinical benefit, currently available agents may present limitations. Several novel antiplatelet medications are currently under advanced clinical testing. Results from ongoing clinical studies will determine the efficacy and safety of these novel agents compared to those currently available.

References (7)

MehtaS.R. et al.
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
Lancet
(2001)
D.J. Angiolillo et al.
Variability in individual responsiveness of clopidogrel: clinical implications, management and future perspectives
J Am Coll Cardiol
(2007)
YusufS. et al.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
N Engl J Med
(2001)

There are more references available in the full text version of this article.

Cited by (2)

Pharmacogenetics in Cardiovascular Antithrombotic Therapy
2009, Journal of the American College of Cardiology
Citation Excerpt :
Unfortunately, standardized definitions of antiplatelet drug responsiveness are lacking. Nevertheless, there are consistent data that patients who persist with increased platelet reactivity despite clopidogrel, also coined as suboptimal clopidogrel responders or clopidogrel-resistant patients, have an increased risk of ischemic events, including stent thrombosis (86). Recent findings (87,88) have shown that a considerable number of patients who are resistant to clopidogrel also may be resistant to aspirin, which further increases their risk of thrombotic complications.
Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke. Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the same degree of benefit from antithrombotic agents, and a considerable number of treated patients will continue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment. Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variability in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters, or targets of a drug all can be implicated in the modification of an individual's antithrombotic drug response and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the modulating role of different polymorphisms on individuals' responses to antithrombotic drugs commonly used in clinical practice.
Research progress of the new platelet aggregation inhibitors
2013, Chinese Pharmaceutical Journal

: Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, J); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Eric R. Bates, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Sanofi-Aventis; Hoffmann-La Roche (Nutley, NJ). Honoraria/Advisory board: Eli Lilly Co; The Medicines Company; Daiichi Sankyo, Inc.; Medicure Pharma (Winnipeg, Manitoba, Canada). Research Grants: Eli Lilly and Company.

View full text

Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction

Lancet

J Am Coll Cardiol

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

N Engl J Med